We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Merck and TAP Biosystems Finalists for “Best Collaboration Award”

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

TAP Biosystems has announced that TAP Biosystems and Merck have been nominated as co-finalists for two awards at the prestigious 2014 BioProcess International (BPI) Awards. The nominations recognize that the ambr250™ System, developed as a result of the collaboration, is a major advance in bioprocessing technology.

At the BioProcess International Awards, TAP Biosystems and Merck have been selected as finalists in the ‘Best Collaboration Award’ and the ‘Best Technology Application - Upstream Award’ categories from amongst numerous outstanding industrial collaborations for their partnership to develop the powerful ambr250 automated mini bioreactor system.

The high-throughput ambr250, co-developed with Merck, has the flexibility to culture mammalian lines, including CHO, or microbial cells, such as Pichia pastoris and E.coli, in single-use, stirred bioreactors utilizing continuous pumped feeds. This means using the ambr250 it is now possible to fully evaluate the process characteristics of large-scale bioreactors and fermenters in weeks rather than months, making the system a significant breakthrough in bioprocessing technology.

For details of all the finalists in the 2014 BPI awards, please go to http://www.bioprocessintl.com/wp-content/uploads/2014/10/BPI-Awards_Finalists_2014.pdf.

Mwai Ngibuini, ambr250 Product Manager at TAP Biosystems commented: “We’re honoured to be shortlisted with Merck for not one, but two BPI awards from such an amazing line-up of bioprocessing advances. Being recognised in these celebrated awards is a great accolade, and further supports the use of ambr250 technology as an excellent strategy for optimizing production of antibody and protein-based therapeutics to pharma and biotech world-wide.”